Dipeptidyl peptidase

Dipeptidyl Peptidase

Dipeptidyl peptidase (DPP) is a type of enzyme that plays a crucial role in the regulation of various physiological processes in the human body. These enzymes are involved in the cleavage of dipeptides from the N-terminus of polypeptides, which is essential for the activation or inactivation of many bioactive peptides.

Types of Dipeptidyl Peptidases

There are several types of dipeptidyl peptidases, each with distinct functions and substrate specificities. The most well-known types include:

• Dipeptidyl Peptidase-4 (DPP-4)
• Dipeptidyl Peptidase-8 (DPP-8)
• Dipeptidyl Peptidase-9 (DPP-9)

Dipeptidyl Peptidase-4 (DPP-4)

DPP-4 is a serine exopeptidase that is widely expressed in various tissues, including the intestine, liver, and kidney. It is involved in the inactivation of incretin hormones such as glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are important for the regulation of blood glucose levels.

Dipeptidyl Peptidase-8 and Dipeptidyl Peptidase-9

DPP-8 and DPP-9 are closely related enzymes that are less well understood compared to DPP-4. They are expressed in various tissues and are thought to play roles in immune regulation and cell proliferation.

Physiological Functions

Dipeptidyl peptidases are involved in numerous physiological processes, including:

• Regulation of glucose metabolism
• Modulation of the immune system
• Control of inflammation
• Regulation of appetite and satiety

Clinical Significance

Dipeptidyl peptidases, particularly DPP-4, have significant clinical implications. Inhibition of DPP-4 is a therapeutic strategy for the treatment of type 2 diabetes mellitus. DPP-4 inhibitors, also known as "gliptins," help to prolong the action of incretin hormones, thereby enhancing insulin secretion and lowering blood glucose levels.

DPP-4 Inhibitors

DPP-4 inhibitors are a class of oral hypoglycemic agents used in the management of type 2 diabetes. Some common DPP-4 inhibitors include:

• Sitagliptin
• Saxagliptin
• Linagliptin
• Alogliptin

Potential Side Effects

While DPP-4 inhibitors are generally well-tolerated, they may cause side effects such as:

• Nasopharyngitis
• Headache
• Upper respiratory tract infection

Research and Development

Ongoing research is focused on understanding the broader roles of dipeptidyl peptidases in health and disease, as well as developing new therapeutic agents targeting these enzymes for various conditions beyond diabetes.

See Also

• Enzyme
• Protease
• Incretin

   This article is a enzyme-related stub. You can help WikiMD by expanding it!